THE Therapeutic Goods Administration (TGA) has issued four infringement notices totalling $75,120 to Queensland-based Summit Pharmacy for the alleged unlawful manufacturing of medicinal cannabis products.
Summit Pharmacy has paid all four infringement notices.
The infringement notices followed an inspection by the TGA and Queensland Health in Aug last year that found the pharmacy was manufacturing medicinal cannabis oils in bulk amounts, in alleged contravention of the Therapeutic Goods Act 1989.
The Act prohibits the manufacturing of therapeutic goods unless the goods are entered in the Australian Register of Therapeutic Goods (ARTG) or subject to an exemption, approval or authority.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Apr 25
